Phase I biotechs Septerna, Orum bolster IPO queue 

Backed by crossover investors from its early days, Septerna now intends to test the IPO market with a NASDAQ offering that will help drive its first clinical GPCR program to a data readout next year. The company is one of three in Phase I testing to announce plans to go public in the past two weeks.

With the filing of its prospectus this week, Septerna Inc. becomes the latest to join an IPO queue that has had an uptick in activity recently. Four biotechs went public in nine-digit offerings on NASDAQ during September, matching the total from mid-April through August...